These findings suggest a crucial role of GAB2 in AML signaling pathways, especially as it amplifies signals from the FLT3-ITD oncoprotein and might thus contribute to the poor prognosis of this patient group and TKI resistance. This evidence concerns the gene FLT3 and acute myeloid leukemia.